Rockford Yapp
Gastroenterology · Downers Grove, ILNPI 1356327910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $291,248 of the $399,148 with a category attached, or 73.0%. It is spread thinly across 56 manufacturers, the largest accounting for just 17.1%. 2025 is the largest year on record at $159,498, 2.8 times the $56,634 reported in 2019. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,307 payments — averaging $305.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Phathom Pharmaceuticals, Inc.$64K
- Novo Nordisk$59K
- Gilead$58K
- Madrigal Pharmaceuticals$49K
- Lumendi LLC$25K
- plus $76K from 50 others
Across 72 payments — averaging $8357.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$322K
- Capsovision, Inc.$264K
- AbbVie$10K
- Novartis$4K
- Braintree Laboratories, Inc.$2K
What the payments were for
- Consulting fees$18,2085%
- Speaking & faculty fees$291,24873%
- Grants$25,0006%
- Travel & lodging$27,1017%
- Food & beverage$37,2269%
- Education$3100%
- Gifts$400%
- Entertainment$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$63,259
- Wegovy$58,049
- REZDIFFRA$46,603
- Mavyret$44,967
- Epclusa$40,167
- XIFAXAN$12,949
- Cimzia$7,325
- COLOGUARD$6,777
- Cologuard Collection Kit$5,500
- Talicia$5,265
- PLENVU$2,119
- LINZESS$1,450
- EVIS EXERA III DUODENOVIDEOSCOPE$875
- Rinvoq$674
- OCALIVA$370
- Skyrizi$358
- GENERAL - THERAPIES$332
- EndoFlip$319
- IQIRVO$292
- TERLIVAZ$287
How this compares
$399,148 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 34 | $196,091 |
| LinzessLinaclotide | 58 | $77,881 |
| ZenpepLipase/Protease/Amylase | 26 | $63,732 |
| XifaxanRifaximin | 16 | $45,465 |
| Mesalamine | 50 | $39,810 |
| CreonLipase/Protease/Amylase | 14 | $39,387 |
| VoqueznaVonoprazan Fumarate | 36 | $33,726 |
| OzempicSemaglutide | 33 | $31,674 |
| Omeprazole | 522 | $9,616 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 135 | $8,550 |
| CholestyramineCholestyramine (With Sugar) | 39 | $3,875 |
| Esomeprazole Magnesium | 78 | $3,578 |
| Lansoprazole | 45 | $1,819 |
| Budesonide DrBudesonide | 13 | $1,662 |
| Pantoprazole Sodium | 84 | $1,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $48,841 | $196,09134 claims |
| AbbVieLinzess, Creon | $68,421 | $117,26872 claims |
| Aimmune Therapeutics, Inc.Zenpep | $313 | $63,73226 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $14,351 | $45,46516 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $64,170 | $33,72636 claims |
| Novo NordiskOzempic | $58,749 | $31,67433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Downers Grove
- Anshuman ChawlaDowners Grove$56K
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Amar NaikDes Plaines$1.2M
- Darren BrennerChicago$1.1M
- Jonathan RosenbergGurnee$1M
- Daksesh PatelEvanston$745K
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.